Analyst Daniel Stauder of JMP Securities reiterated a Buy rating on Artivion (AORT – Research Report), retaining the price target of $33.00.
Daniel Stauder has given his Buy rating due to a combination of factors that highlight Artivion’s strong fundamentals and growth potential despite recent challenges. The company experienced a temporary setback due to a cybersecurity incident, which affected its tissue preservation division and led to a revenue shortfall in the fourth quarter of 2024. However, management has indicated that operations have returned to normal, and the impact is expected to be short-lived, with recovery anticipated over the rest of the year.
Stauder points to several positive indicators that support the Buy rating. Artivion’s initial revenue guidance for 2025 suggests a robust year-over-year growth, and the company’s adjusted EBITDA guidance also indicates significant improvement. Additionally, new product developments, such as the commercialization of BioGlue in China and the anticipated FDA approval for NEXUS, are expected to contribute to future growth. The current trading multiple does not fully reflect the company’s potential, making it an attractive investment opportunity, especially if there is a pullback due to the recent incident.
In another report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $35.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com